Biopharma AI
By
Is Biopharma’s $8.5 Billion AI Investment in 2025 Across Discovery, R&D, and Commercialization Shaping the 2026 Innovation Landscape?
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma, Healthcare, and AI Infrastructure?
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
How Did Merck’s 2025 Deals Strengthen Its Pipeline and What Could They Mean for Future Growth?
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in 2026?
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66 Million NLRP3 Licensing Deal
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
